Stephen S. Yoder - 22 Feb 2022 Form 4 Insider Report for PIERIS PHARMACEUTICALS, INC. (PVLA)

Role
Chief Executive Officer, Director
Signature
/s/ Megan Gates, Attorney-in-Fact
Issuer symbol
PVLA
Transactions as of
22 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 15:44:25 UTC
Next filing
28 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PIRS Stock Option (Right to buy) Award $0 +625,874 $0.000000 625,874 22 Feb 2022 Common Stock 625,874 $3.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the option shares on February 22, 2023 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.